Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424239 · ClinicalTrials.gov registry record · Phase 4
Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03424239: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03424239 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03424239, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
Interventions
- DIETARY_SUPPLEMENT Vitamin D3
- DRUG Zoledronic Acid
- DIETARY_SUPPLEMENT Calcium citrate + vitamin D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2020-01-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03424239
The ClinicalTrials.gov registry entry for NCT03424239 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vitamin D3 is the first listed.
NCT03424239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03424239 about?
NCT03424239 is a clinical study titled "Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery". This study evaluates whether zoledronic acid can prevent the high bone turnover that occurs after Roux-en-Y Gastric Bypass (RYGB) and sleeve gastrectomy (SG) surgery.
What is the current status of trial NCT03424239?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-08-01. Estimated completion is 2020-01-01.
What interventions are being tested in trial NCT03424239?
The interventions under investigation include: Vitamin D3 (DIETARY_SUPPLEMENT), Zoledronic Acid (DRUG), Calcium citrate + vitamin D (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03424239?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.